Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03515096
Recruitment Status : Recruiting
First Posted : May 3, 2018
Last Update Posted : March 12, 2019
Sponsor:
Information provided by (Responsible Party):
Shenzhen Second People's Hospital

Brief Summary:
The primary objective is to compare the efficacy of eltrombopag vs rhTPO in complete response in patients after HSCT in China. This is a post-marketing, interventional, single-center, double-arm, prospective, open-label, equivalent, randomized controlled study in adult patients with hematopoietic stem cell transplantation in China. Patients will be recruited consecutively from the study sites during the enrollment period. The enrolled patients will be given eltrombopag or rhTPO under the conditions of informed consent and frequent monitoring according to the clinical guideline.

Condition or disease Intervention/treatment Phase
Eltrombopag Hematopoietic Stem Cell Transplantation Thrombocytopenia Drug: Eltrombopag Drug: rhTPO Phase 3

Detailed Description:

Hematopoietic stem cell transplantation (HSCT) is an important method to treat malignant tumor of blood system, and promoting platelets after HSCT is one of the important factors to determine the success of transplantation.

Recently, the main effective method to treat thrombocytopenia after transplantation is to preventively transfuse platelets. However, this method can cause platelet transfusion related graft-versus-host disease(GVHD), increase the risk of reaction and infection associated with blood transfusion, easily produce platelet related and specific antibodies (HPA), which seriously affect the curative effect of platelet infusion and even render platelet transfusion invalid. Besides, study has shown that the effective rate of platelet transfusion is 30%-70%, and the application of platelets in clinic is limited because of the shortage of blood supply at present.

Recombinant human thrombopoietin (rhTPO) is a glycoprotein molecule modified by full-length glycosylation and is of a similar pharmacological effect with endogenous thrombopoietin (TPO). TPO is a specific cytokine of megakaryocyte, which can promote the proliferation and maturation of macronuclear progenitor cells by binding to the receptor c-mpl. In addition, the chinese State Food and Drug Administration (SFDA) approved rhTPO for the treatment of thrombocytopenia after tumor chemotherapy in 2006. The study shows that rhTPO can increase the mean value of platelet count in the low period of platelet, shorten the time of low platelet, and improve the peripheral blood platelet aggregation rate in the bone marrow depression period.

Eltrombopag is the first oral non-peptide receptor (TPO-R) agonist, which can induce the proliferation and maturation of macronuclear progenitor cells via the Janus kinase (JAK) /signal transducer and activator of transcription (STAT) pathway. In 2008, the U.S. FDA approved the use of eltrombopag for the treatment of chronic idiopathic thrombocytopenia, and it has been widely used in tumor patients with thrombocytopenia after chemotherapy. Tanaka et al. have proved that eltrombopag can improve the average elevation of the platelet count in the bone marrow depression period in patients with stem cell transplantation. Besides, within the 9 patients receiving transplantation, the complete response of patients with primary and secondary thrombocytopenia were 60% and 71% respectively.

In China, studies showed that rhTPO could promote the recovery of platelet count, effectively reduce the infusion of platelet, decrease the risk of transplanting hemorrhage in acute leukemia patients after allo-HSCT. However, it is not clear that the effect of eltrombopag on improving platelet count after the treatment of HSCT. In addition, the comparison of efficacy and safety of eltrombopag vs rhTPO on platelet recovery after HSCT in clinical trial is not investigated. Therefore, it is of great significance to explore the efficacy and safety of eltrombopag and rhTPO in improving the recovery of platelet count after HSCT, which will provide a better method to recover platelet after HSCT.

The purpose of this study is to compare the efficacy of Eltrombopag vs rhTPO in complete response in patients after HSCT in China. To be more precise, Eltrombopag is taken 50 mg po daily from day 1 until platelet is completely effectively recovered after HSCT, while rhTPO is given by subcutaneous injection 15000 u daily from day 1 until platelet is completely effectively recovered after HSCT.

Complete response (CR) is defined as a platelet count more than 50×109/L without injection of platelet for 7 days. Partial response (PR) is defined as a platelet count more than 30×109/L without injection of platelet for 7 days.

After 21 days' treatment, a follow-up of all patients will be performed every week in the following 3 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 156 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Eltrombopag vs. Recombinant Human Thrombopoietin to Increase Platelet Level After Hematopoietic Stem Cell Transplantation: an Equivalent, Open-label, Randomized-controlled Study
Actual Study Start Date : July 1, 2018
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : June 1, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Eltrombopag

Arm Intervention/treatment
Experimental: Eltrombopag
Thrombopoietin- receptor (TPO-R) agonist
Drug: Eltrombopag
Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
Other Names:
  • Promacta
  • Revolade

Placebo Comparator: rhTPO
Recombinant human thrombopoietin (rhTPO)
Drug: rhTPO
rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
Other Name: no other name




Primary Outcome Measures :
  1. Number of Participants (Responders) Achieving a Platelet Count >=50×10^9/L On Day 21 After HSCT [ Time Frame: From the start of study treatment (Day 1) to days 21 ]
    On days 21 after HSCT, the number of participants (responders) with platelet count >=50x10^9/L and no platelet infusion for 7 days were compared between treatments


Secondary Outcome Measures :
  1. Number of Participants (Responders) Achieving a Platelet Count >=30×10^9/L On Day 21 After HSCT [ Time Frame: From the start of study treatment (Day 1) to days 21 ]
    On days 21 after HSCT, the number of participants (responders) with platelet count >=30x10^9/L and no platelet infusion for 7 days were compared between treatments

  2. Number of Participants (Responders) Achieving a Platelet Count >=100×10^9/L On Day 21 After HSCT [ Time Frame: From the start of study treatment (Day 1) to days 21 ]
    On days 21 after HSCT, the number of participants (responders) with platelet count >=100x10^9/L and no platelet infusion for 7 days were compared between treatments

  3. Number of Participants With Bleeding events as Assessed Using the predefined bleeding scoring system. [ Time Frame: From the start of study treatment (Day 1) to days 90 ]
    The predefined bleeding scoring system is a measure of bleeding severity with the following score: score 0 = no bleeding, score 1= occult blood in body secretions (detected by heme-positive dipstick), mild petechiae, or minimal vaginal spotting, score 2= minor bleeding that does not require red blood cells (RBC) transfusions over routine transfusion needs (epistaxis, vaginal bleeding, mild hematemesis, melena, and mild hematuria) 3 = hemorrhage causing rapid decrease in hematocrit level, necessitating one or more units of RBCs per day beyond routine transfusion needs, and score 4 = Life-threatening hemorrhage, defined as either massive bleeding causing severe hemodynamic compromise or bleeding into vital organ (e.g., intracranial hemorrhage, pericardial, or diffuse alveolar hemorrhage).

  4. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) [ Time Frame: From the start of study treatment (Day 1) to days 90 ]
    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, is a congenital anomaly/birth defect or is associated with protocol specified liver injury and impaired liver function or is any protocol specific AEs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18;
  • Patients who have undergone hematopoietic stem cell transplantation (HSCT);
  • Patients who don't take any drug including Eltrombopag and rhTPO before hematopoietic stem cell transplantation (HSCT);
  • Patients receiving either an autologous (Auto) or allogeneic (Allo) stem cell transplantation from a sibling,related donor, or matched unrelated donor are included;
  • Agree to sign informed consent

Exclusion Criteria:

  • Patients with thrombocytopenia causes by other reasons, such as drugs, cytomegalovirus or infection;
  • Patients who had greater risk of thromboembolic disease within six months;
  • Patients with a history of heart disease;
  • Patients with severe organ dysfunction;
  • Patients with other malignancies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03515096


Contacts
Layout table for location contacts
Contact: XIN DU, MD 075583366388 ext 8195 duxingz@medmail.com.cn

Locations
Layout table for location information
China, Guangdong
Shenzhen Second People's Hospital Recruiting
Shenzhen, Guangdong, China, 518035
Contact: Xin Du, MD    075583366388 ext 8196    duxingz@medmail.com.cn   
Sponsors and Collaborators
Shenzhen Second People's Hospital
Investigators
Layout table for investigator information
Principal Investigator: XIN DU, MD Second People's Hospital of Shenzhen

Layout table for additonal information
Responsible Party: Shenzhen Second People's Hospital
ClinicalTrials.gov Identifier: NCT03515096     History of Changes
Other Study ID Numbers: 201803070044
First Posted: May 3, 2018    Key Record Dates
Last Update Posted: March 12, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Shenzhen Second People's Hospital:
rhTPO
HSCT
Thrombopoietin
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombocytopenia
Blood Platelet Disorders
Hematologic Diseases